The Money Is Still Moving and It’s Targeting the Heart
Editor’s Note: AI isn’t just changing how we diagnose it’s redefining how MedTech creates value. October proved that investors now prize AI platforms that slot into clinical workflows and translate precision into profitability. Here’s what’s driving that capital momentum across cardiology and beyond.
Cleerly and Cigna: Coverage Becomes Currency
In late September, Cigna Group approved national coverage for Cleerly’s AI-based coronary imaging technology, extending access to more than 60 million Americans.
That move does more than validate a product it validates an entire category. AI-enabled coronary plaque quantification is now a reimbursable service, and that changes the economics overnight.
Hospitals and imaging centers equipped with Cleerly’s platform can turn precision diagnostics into billable, value-based outcomes. For investors, it’s the moment when regulatory clearance converts into revenue momentum and when adoption becomes inevitable.
🔗 Cigna Approves Coverage for Cleerly’s AI Cardiovascular Imaging Technology (BusinessWire)
AngioInsight’s $25 Million Bet on Coronary AI
AngioInsight, based in Minnesota, announced a $25 million Series A to scale its AngioAI+™ platform for diagnosing coronary artery and microvascular disease.
It also brought Shlomi Nachman, former Worldwide Chairman at Johnson & Johnson Cardiovascular, onto its board a clear signal that leadership from traditional medtech is converging with AI upstarts.
The platform isn’t just predicting plaque; it’s built to plug directly into cath-lab workflows. The message from the market is unmistakable: integrated clinical platforms, not isolated algorithms, are where the next wave of value will be captured.
HeartFlow’s Precision Push
HeartFlow’s latest FDA clearance for its upgraded AI-driven plaque analysis tool keeps it at the center of the cardiovascular AI conversation.
By improving how plaque is classified and mapped, HeartFlow is enabling clinicians to make faster, more accurate triage decisions reducing unnecessary invasive procedures and cutting system costs.
Cardiovascular disease remains the largest cost driver in healthcare. HeartFlow’s model tackles that cost base directly: precision isn’t just better medicine, it’s better economics.
🔗 HeartFlow’s Updated Coronary Plaque Analysis AI Nets FDA Clearance (Fierce Biotech)
Regulation, Realism, and the Next Phase
The latest Heart journal editorial “AI Adoption in Cardiology: Regulation at a Global Crossroad” (Sept 24, 2025) revealed that nearly 300 AI/ML cardiology devices have already been cleared by the FDA, with 97% via the 510(k) pathway.
That’s both progress and pressure. Regulatory clearance is no longer the finish line it’s the starting gate. The winners now will be those that convert clearance into clinical use, and clinical use into economic leverage.
🔗 AI Adoption in Cardiology: Regulation at a Global Crossroad (Heart Journal)
Heidi Health and the Workflow Premium
Beyond cardiology, the money is following the same signal. Heidi Health closed a $65 million Series B led by Point72, building an AI-powered medical scribe and automation platform now valued at $465 million.
Its model reclaiming physician time and tightening documentation mirrors the same logic driving cardiology AI: reduce friction, reduce waste, protect margin.
In a system under relentless cost pressure, workflow AI is the new infrastructure.
🔗 Exclusive: Heidi Health Raises $65 Million Series B (Business Insider)
October’s Lesson for the Market
October made it official: AI is no longer experimental in MedTech. It’s the foundation of strategy.
The investment flow is rewarding platforms that can prove one thing that clinical precision is economic value.
The companies pulling away from the pack are those that turn regulatory progress into adoption, and adoption into financial outcomes.
For investors, the playbook is clear: Follow the platforms that make data profitable.
.png)
.png)